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Abstract
Background: Chronic kidney disease (CKD) is the focus of recent national policy efforts; however, decision makers
must account for multiple therapeutic options, comorbidities and complications. The objective of the Chronic
Kidney Disease model is to provide guidance to decision makers. We describe this model and give an example of
how it can inform clinical and policy decisions.
Methods: Monte Carlo simulation of CKD natural history and treatment. Health states include myocardial infarction,
stroke with and without disability, congestive heart failure, CKD stages 1-5, bone disease, dialysis, transplant and
death. Each cycle is 1 month. Projections account for race, age, gender, diabetes, proteinuria, hypertension, cardiac
disease, and CKD stage. Treatment strategies include hypertension control, diabetes control, use of HMG-CoA
reductase inhibitors, use of angiotensin converting enzyme inhibitors, nephrology specialty care, CKD screening,
and a combination of these. The model architecture is flexible permitting updates as new data become available.
The primary outcome is quality adjusted life years (QALYs). Secondary outcomes include health state events and
CKD progression rate.
Results: The model was validated for GFR change/year -3.0 ± 1.9 vs. -1.7 ± 3.4 (in the AASK trial), and annual
myocardial infarction and mortality rates 3.6 ± 0.9% and 1.6 ± 0.5% vs. 4.4% and 1.6% in the Go study. To illustrate
the model’s utility we estimated lifetime impact of a hypothetical treatment for primary prevention of vascular
disease. As vascular risk declined, QALY improved but risk of dialysis increased. At baseline, 20% and 60% reduction:
QALYs = 17.6, 18.2, and 19.0 and dialysis = 7.7%, 8.1%, and 10.4%, respectively.
Conclusions: The CKD Model is a valid, general purpose model intended as a resource to inform clinical and
policy decisions improving CKD care. Its value as a tool is illustrated in our example which projects a relationship
between decreasing cardiac disease and increasing ESRD.
Keywords: chronic kidney disease, decision model, markov model
Background
Chronic kidney disease (CKD) affects 13% of the US
population and its incidence is increasing with the rise
in major CKD risk factors, hypertension and diabetes[1].
An expanding body of evidence indicates that early con-
trol of hypertension and diabetes and the use of angio-
tensin converting enzyme inhibitors (ACEIs) can reduce
progression of CKD and improve outcomes of those
who do progress to end stage disease (ESRD)[1-3]. As a
consequence, CKD has become the focus of local and
national health policy efforts to promote screening and
early initiation of therapy[4-6].
Among various interventions available for CKD, multi-
ple clinical and policy questions arise. Which interven-
tions provide improved health outcomes, when
considering potential adverse effects, uncertain effective-
n e s s ,a n dt h el i k e l i h o o dt h a te v e n t ss u c ha sm y o c a r d i a l
infarction (MI) may be more likely than end-stage renal
d i s e a s e( E S R D ) ?D ot h eh e a l t hb e n e f i t sc o m ea ta n
acceptable cost? How do providers account for both the
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epidemiology of CKD, which involves multiple, changing
risk factors and competing comorbidities?
Decision modeling can assist in health care decisions
for complex diseases like CKD by simulating disease
progression while accounting for uncertainties in out-
comes using a range of possible scenarios. Several mod-
els have been developed to address specific issues
related to CKD[7-9], but they have been designed for
special purposes and are usually not publically available.
As a consequence, analysts must start the modeling pro-
cess from scratch with each new question. Moreover,
inputs to the model such as the probability of disease
progression which are conditional on patient character-
istics must be re-estimated with each project. One strat-
egy to avoid this inefficiency is to create a model
sanctioned by a major governmental agency, profes-
sional organization, or other accountable entity. Another
strategy is to develop a general-purpose, publicly avail-
able model. These models are flexible enough to address
a wide variety of clinically-and policy-relevant questions
and are freely available to researchers and clinicians.
The notion is that such a model could serve to promote
a more informed decision-making process by allowing
for consistent evaluation of various treatment strategies,
and ongoing feedback from users who are encouraged
to participate in the continuous improvement of the
model in a public forum.
In this paper, we describe such a general-purpose,
publicly available model and illustrate its potential as a
tool for CKD healthcare with an example: the impact of
a treatment to reduce cardiovascular risk in individuals
with CKD.
Methods
Overview
The model is constructed to provide, for a defined
population undergoing several intervention scenarios,
the likelihood of a variety of outcomes important to
decision makers: death, ESRD, MIs, strokes, bone dis-
ease, and rate of CKD progression.
Though the illustration here focuses on a hypothetical
treatment that reduces cardiovascular risk, the model is
designed to accommodate 7 specific interventions that
affect the natural history of disease. These 7 strategies
include: treatment with an ACEI, treatment with an
HMG-CoA Reductase Inhibitor, management by a
nephrologist, control of diabetes, control of hyperten-
sion, calcium and phosphorous management, and imple-
mentation of a CKD screening program. The model
allows the evaluation of interventions on either a static
or dynamic population. A static population is the basis
of a traditional cohort decision model that follows a pre-
defined group of individuals over their lifetime, while a
dynamic population permits individuals to enter and
leave the cohort over time. Dynamic modeling is the
basis of community impact models, which provide esti-
mates for the burden of disease in people living in a
given catchment area, and it provides projections for a
defined time horizon. In this paper we provide the
results of a hypothetical treatment for a static cohort.
To guide the development of the model, we convened
a panel of health policy and nephrology experts. During
group meetings we elicited two lists: (1) patient charac-
teristics judged to influence management by virtue of
being known or strongly suspected to predict natural
history, effectiveness/risk of treatment, cost, or quality
of life/utility; and (2) outcomes that the model should
be able to produce in order to promote informed deci-
sion making. In addition, when model input values were
not available in the literature, we solicited opinion from
our expert panel.
Population
Assigned population characteristics include race, age,
gender, diabetes, proteinuria, hypertension, pre-existing
cardiovascular disease, calcium/phosphorous abnormal-
ities, and initial CKD stage. CKD stages are defined
according to the National Kidney Foundations Practice
Guidelines: stage 1 (GFR ≥90 with proteinuria or hema-
turia), stage 2 (GFR 60-89 with proteinuria or hema-
turia), stage 3 (GFR 30-59), stage 4 (GFR 15-29), stage 5
(GFR < 15)[10]. These cohort parameters may be modi-
fied to suit an individual user’s need and context. For
example they may be set to represent the characteristics
of the CKD population of California or to 50-year-old
diabetics. The default population is the United States
CKD population, based upon data from the National
Health and Nutrition Examination Survey (NHANES)[1]
(Table 1).
Model Structure
The foundation of the model is a “natural history” Mar-
kov Monte Carlo simulation with a discrete cycle length
of one month (TreeAge Pro 2007, Release 1.0.2, 2009).
A Monte Carlo is a patient-level simulation, which
simulates the life of one individual at a time. The advan-
tage of this type of simulation is that it permits tracking
of prior health states (past events) and uses this infor-
mation to account for the development of new risk fac-
tors and events. In addition, it addresses variability in
input values by estimating outputs as distributions or
summary statistics such as a mean and 95% confidence
interval.
During each cycle, an individual may remain in their
current health state or enter a new one. Health states
include: CKD stages 1-5 and dialysis, bone disease, MI,
congestive heart failure (CHF), stroke without disability,
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and death (Figure 1). In addition to changing health
states individuals may develop comorbid conditions
including diabetes, hypertension, or calcium/phosphor-
ous abnormalities during each cycle. Once a comorbid
condition develops, it remains with the patient for life
and may alter future transition probabilities to other
health states.
Once the GFR declines to 10 ml/min or less, either
hemodialysis or kidney transplantation is initiated. Peri-
toneal dialysis is not included in the model since it only
accounts for approximately 2% of individuals starting
dialysis[11] and would further complicate the model
without having any significant impact on outcomes.
From here forward the term dialysis is used to mean
hemodialysis only. At the time of dialysis initiation an
individual may or may not have a mature fistula in
place. The likelihood of having a functional fistula is set
at a default value of 25% but may be modified by the
user to evaluate the impact of a program implementing
fistulas at higher GFRs. In the case of transplantation,
the transplant may survive or fail. If it fails, the indivi-
dual is assumed to revert to dialysis for the remainder
of their lifespan.
Model Parameters
Event Probabilities
During each monthly cycle individuals have a probability
of developing calcium/phosphorous abnormalities (cal-
cium < 8.4 mg/dL and phosphorous > 4.6 mg/dL)
(Table 2) and diabetes (Table 3), as well as stage-depen-
dent CKD complications such as hypertension (blood
pressure > 135/85 mmHg) (Table 2).
The probability of outcome events: bone disease, GFR
change, MI, stroke, disability from stroke, CHF, cardio-
vascular disease-related death, and non-cardiovascular
disease-related death are derived from the literature.
Values for MI, stroke, bone disease, GFR change, and
death are dependent upon the current CKD stage (Table
2), while the probabilities for disability from stroke,
death from MI, and CHF from MI are not (Table 3).
GFR change ranges from improvement to decline based
upon a distribution adjusted for age, race, current CKD
stage, hypertension, diabetes, proteinuria, and cardiovas-
cular disease derived from an analysis of a primary data-
set of CKD patients followed for 5 years at the Durham,
NC Veteran’s Affairs Hospital[12]. Being derived from a
VA dataset has potential limitations in generalizeability;
however it allows a detailed analysis of the normal dis-
tribution around monthly GFR changes and the specific
impact of each variable, singly and combined. This level
of detail is not available through other mechanisms and
to explore whether the GFR change values perform
appropriately we externally validate cohort GFR changes
in the model against the AASK study as described in
the validation section.
Utilities
Utilities reflect patients’ preferences for health states and
are used to provide an estimate of the quality of life
experienced by individuals in those states. Values range
from 0, defined as dead, to 1, defined as perfect health.
The utilities in our simulation are derived from the lit-
erature (Table 3). Since acute MI and stroke are tem-
porary but serious events that profoundly reduce quality
of life, individuals experience lowered utilities for the
month following these events. Since the post MI, post
stroke, stroke-related disability, bone disease, and CHF
states are permanent their utilities are applied for the
remainder of the analysis.
The utility for kidney transplant was defined as the
value three-fourths of the distance on the utility scale
between dialysis (0.8)[13] and perfect health (1.0), or
0.95. This value was chosen since transplant has consis-
tently been shown to have a much higher quality of life
Table 1 Cohort baseline characteristics
Variable Description CKD Stage 1 CKD Stage 2 CKD Stage 3 CKD Stage 4 CKD Stage 5 Data Sources
Male 65.80% 56.5% 37.8% 35.9% 35.9% [19]
White race 39.5% 48% 47.5% 43.5% 20% [19]
Age 20-30 55.1% 16% 1.90% 1.50% 0% [19]
Age 40-59 25.1% 34% 4.8% 1.5% 5% [19]
Age 60-69 10.1% 23% 23.2% 30.2% 10% [19]
Age > 69 9.70% 27% 69.70% 66.80% 85% [19]
CKD stage 30.3% 27.2% 39.0% 2.6% 1.5% [19]
Proteinuria 14.3% 14.3% 6.1% 42.6% NA [1]
Diabetes 18.9% 22.1% 16.9% 17.1% 17.1% [20]
Hypertension 24.1% 35.3% 46.5% 51.6% 94% [19]
Calcium/Phosphorous abnormalities 3% 15% 50% 70% 85% [21]
Pre-existing Cardiovascular disease 10% 12.9% 17.6% 25% 60% [17]
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the immunosuppressive regimens and risk of infections
[14]. In order to assess the impact of this assumption,
we perform sensitivity analyses using values that range
from dialysis to perfect health.
Treatment effects
As described above the model accommodates 7 different
treatment strategies: treatment with an ACEI or ARB,
treatment with an HMG-CoA Reductase Inhibitor, man-
agement by a nephrologist, control of diabetes (HgbA1c
< 7.0%), control of hypertension (blood pressure < 135/
85 mmHg), calcium and phosphorous management (cal-
cium 8.4-9.5 mg/dL and phosphorous 2.7-4.6 mg/dL)
and implementation of a CKD screening program.
Treatment effects take into account the likelihood of
being adherent with the therapy, due to either non-
adherence or adverse events, and are applied as relative
risk reductions on the probability of each outcome,
except in the case of implementation of a screening pro-
gram. In the screening strategy we simulate a dynamic
cohort, which permits the addition of newly identified
early stage CKD patients into the model during each
cycle. This number varies based upon the characteristics
of the population being screened (high risk versus low
risk); however default values are derived from the KEEP
study[15].
To demonstrate how the model can be used to
explore the impact of treatments with a range of effi-
cacy, we provide an example of a hypothetical treatment
(TREATMENT A) that decreases the development of
asymptomatic pre-clinical coronary artery and carotid
artery disease by an unknown amount. In this example
we show how various levels of efficacy, ranging from
none to 80%, impact different endpoints, particularly
development of end-stage renal disease, stroke, and MI.
For simplicity, we assumed that patients were comple-
tely adherent to treatment and there were no adverse
treatment events.
Base Case Analysis
Each Markov Monte Carlo simulation consists of 10,000
individuals, each put through the natural history and
Table 2 The monthly probability of developing CKD-related complications or conditions and the monthly change in
GFR by CKD stage
Variable Description CKD Stage 1 CKD stage 2 CKD stage 3 CKD stage 4 CKD stage 5 Data Source
Hypertension 0.08% 0.4% 0.6% 0.6% 0.6% [22,23]
Incidence of calcium/phosphorous abnormalities 0.001% 0.005% 0.01% 0.01% 0.03% [19]
Bone disease (in those with calcium imbalance) 0% 80% 90% 100% 100% [19]
Stroke 0.003% 0.003% 0.003% 0.006% 0.006% [24]
MI (no pre-existing CVD) 0.05% 0.07% 0.13% 0.13% 0.48% [25]
MI (with pre-existing CVD) 0.27% 0.31% 0.50% 0.50% 1.00% [25]
Figure 1 Markov Model tree structure and monthly state
diagram. Figure 1a Markov Model tree structure up to the
monthly Markov cycle. The initial decision comparison is
between the natural history core and a treatment strategy. The
treatment strategy arm accounts compliance with therapy by
p u t t i n gt h o s ew h os t o pt h e r a p yback into the natural history
core. The health states incorporated into the model are those at
risk for CKD, the CKD stages, dialysis, kidney transplant, and
death. Figure 1b State diagram displaying health states of the
Markov monthly cycle. Each month an individual may remain in
their current CKD stage, change CKD stage (either improving or
declining a stage), enter dialysis or transplantation, develop bone
disease, have a myocardial infarction, have a stroke from which
they become disabled, have a stroke from which they are not
disabled, or die. The likelihood of these events occurring are
dependent upon the presence of specific covariates as well as
the current CKD stage.
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we calculate QALYs by determining the number of
months spent in each health state, multiplying by the
appropriate utility, summing to get quality adjusted life
months and dividing by 12. Because individuals place
greater value on events occurring in the present than
the future, utility values are discounted by 3% per year
as the cohort ages while traversing the model.
Implementing the model as a Markov Monte Carlo
simulation allows tracking of specific events; in this case
we track the number of MIs and strokes experienced by
each individual, as well as the development of diabetes,
hypertension, bone disease, ESRD, CKD progression and
CHF. These values are averaged over the 10,000 indivi-
duals and compared between strategies to determine the
net change (and 95% CI) attributable to the intervention.
For our example we perform a one-way sensitivity
analysis of the relative risk reduction in asymptomatic
pre-clinical vascular disease (RRRvasc) associated with
TREATMENT A. The QALYs, MIs, strokes, and deaths
are calculated using a range of values for the relative
risk reduction, from 0 to 0.80. To externally validate the
CKD model, we alter the model’s cohort to reflect parti-
cipants of two different published studies and compare
the model’s projections to theirs. The first study is the
AASK trial[16] and the second is the study by Go et al
(AS Go NEJM 2004)[17].
Sensitivity Analysis
In conventional sensitivity analysis, one, two, or more
input values are varied over their plausible range to
examine the impact on the relative preference for one
intervention strategy over another. If such changes influ-
ence which strategy is preferred, or if the results of the
model substantially change the relative preference of the
two strategies, then the model is deemed sensitive to
the variable; if the results do not change then the model
is considered robust with regard to the variable and its
input values. In addition to examining the relative
importance of input variable on the estimated outcomes,
sensitivity analysis can also be used to identify circum-
stances in which one strategy would be preferred over
another.
In our illustration we examine each variable while also
varying the relative risk reduction for asymptomatic pre-
clinical vascular disease (RRRvasc), in order to assess
the impact of the variable at each level of relative risk
reduction.
Results
Validation
We compare model outputs for myocardial infarction
and mortality rates to those in the Go study and GFR
change to those in the AASK trial. Rates for all com-
pared outcomes are similar. Specifically, annual myocar-
dial infarction and mortality rates are 3.6 ± 0.9% and 1.6
± 0.5%, respectively in the model and 4.4% and 1.6% in
the Go study[17]. GFR change in the model is -3.0 ± 1.9
ml/min/year versus -1.7 ± 3.4 ml/min/year in AASK
[16]. Sensitivity analyses did not alter our findings in
either the baseline analysis or for the external
validations.
In our base case analysis (when RRRvasc = 20% reduc-
tion), use of TREATMENT A for the primary preven-
tion of cardiovascular disease, results in 18.2 QALYS as
compared to 17.6 QALYS in the natural history arm.
The lifetime risk for the US CKD cohort for MI (52% vs
75%) and cardiovascular disease mortality (5.0% vs 5.7%)
is decreased by Treatment A, while the lifetime risk of
stroke and stroke-related disability are unchanged and
the lifetime risk of dialysis is increased (8.1% vs 7.7%).
Therefore, if it is applied across the US CKD population
(~ 40,000,000 individuals),[1,18] Treatment A would
decrease the number of MIs by 9,200,000 and the
Table 3 Variables not dependent upon the current CKD
stage
Variable Description Value Data
Source
Utility of acute MI or stroke 0.1 opinion
Utility of CHF 0.76 [26]
Utility of death 0 [13]
Utility if disabled from stroke 0.35 [27]
Utility of dialysis 0.8 [13]
Utility of transplant 0.95 opinion
Monthly incidence of diabetes 0.005% [28,29]
Probability of death from acute MI [mean (range)] 8% (1-
15)
[30]
Probability of CHF after acute MI [mean (range)] 5% (1-
15)
[31,32]
Probability of moderate-severe disability after
stroke
33% [33]
Probability of death from acute stroke 20% [34]
Probability of choosing hemodialysis for renal
replacement therapy
97.70% [11]
GFR Threshold for placing fistula 30 ml/
min
[11]
Monthly probability of fistula placement 25% [11]
Monthly mortality first year on dialysis with
catheter
4.25% [35]
Monthly mortality after first year on dialysis with
catheter
1.47% [11]
Monthly mortality on dialysis with fistula 1.33% [35]
Probability of choosing transplant for renal
replacement therapy
2.30% [11]
Mortality during transplant surgery 1.20% [36]
Monthly probability of transplant failure 0.51% [11]
Monthly mortality with transplant 0.31% [11]
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increase the number of individuals starting dialysis by
160,000.
The lifetime risk of MI, stroke, stroke-related disabil-
ity, dialysis, and cardiovascular-related death are
reported across 4 levels of RRRvasc (20% to 80%) in
Table 4. While MI and cardiovascular death are reduced
at all levels of risk reduction, stroke and stroke-related
disability are not reduced until the risk reduction
reaches 60%. The mean CKD stage at death was 2.2.
Discussion
The burden of CKD is expanding rapidly as are the risk
factors for developing kidney disease. Appropriate and
early care can both lower the incidence of ESRD and
improve the outcomes of CKD; however, the complex
n a t u r eo fk i d n e yd i s e a s ea n dt h ef a c tt h a ti tr e m a i n s
silent until late in its course has made implementing
appropriate therapies difficult. This complexity lends
itself well to decision modeling, which is designed to
explore the role of competing risks and benefits within a
context that incorporates patient centered values into
outcomes as “quality adjusted life”. For these reasons
decision modeling is an ideal tool to aid decision makers
and promote informed clinical and public policy. To this
end we developed a general-purpose model designed to
evaluate the impact of 7 different treatment strategies
on outcomes including QALYs, mortality, cardiovascular
disease, disease progression, and bone disease. This
paper serves as an introduction to both the model and
its methodology.
As a general-purpose model it is designed to be
freely available for non-commercial purposes by aca-
demics and public policy analysts. Our intent is to
make it as transparent as possible and to permit
ongoing external validation by other users. We antici-
pate that this process will generate continuous feed-
back and that new data will continue to become
available in the literature. Therefore, we designed the
CKD model to be easily updated with new variable
estimates and new treatment strategies on an ongoing
basis using standard software, so that it may remain a
useful and reliable tool.
Preliminary efforts at model validation are promising.
We perform extensive sensitivity analysis as well as
external validation of model outputs compared to data
from cohorts not used to estimate current model inputs.
We did not identify any variables that significantly chan-
ged the outcome results when varied across their plausi-
ble range. Also, external validation indicates that key
model outcomes from two published studies: the AASK
trial[16] and the Kaiser Cohort as reported by Go[17]
are comparable to the results of the model when
accounting for the characteristics of patients from those
studies.
In addition to yielding comparable event rates, when
comparing model results with AASK data on GFR tra-
jectory, the results are similar. This is notable since the
GFR equation is derived from a VA population and
GFR modifies the risk of all outcomes. The ability to
replicate the results seen in the AASK trial suggests that
the model is generally applicable, providing reasonable
estimates across various CKD populations, and ade-
quately simulates the impact of blood pressure control
and ACEI/ARB treatment.
As an introduction to how the model can be used and
how the results may benefit decision-making, we illus-
trate the case of a hypothetical treatment that reduces
the incidence of new cardiovascular disease. The results
show how the major CKD health states interact with
each other. Stroke, which can be severely disabling, is
rare enough that therapies designed specifically for
reduction in stroke alone will have limited effect on the
population as a whole, while MI is so common that
decreasing cardiac events has a tremendous impact on
mortality. It also illustrates the complex nature of kid-
ney disease and the importance of competing risks and
benefits, as seen by the rise in the number of dialysis
patients as cardiovascular disease declines. This has
important implications for costs of care and suggests
that while the prevention of cardiac disease is impera-
tive, if implemented alone without concomitant thera-
pies to decrease progression to ESRD is likely to
increase ESRD costs.
A major limitation to decision modeling is the quality
of the inputs. Inaccuracy or imprecision in the inputs
Table 4 Model output for quality adjusted life years (QALY) and lifetime risk for dialysis, MI, stroke, disabled status,
and cardiovascular disease mortality for the cohort across a range of relative risk reductions (RRR) associated with the
primary prevention of cardiovascular disease (CVD)
Value of RRR for prevention of CVD QALYs Dialysis MI Stroke Disabled CVD Mortality
Baseline 17.6 7.7% 75% 0.7% 0.2% 5.7%
20% 18.2 8.1% 52% 0.7% 0.2% 5.0%
40% 18.5 9.0% 40% 0.7% 0.1% 3.1%
60% 19.0 10.4% 32% 0.5% 0% 2.4%
80% 19.2 11.3% 16.3% 0.2% 0% 0.8%
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precision of the outputs. We address this issue of data
quality, particularly those surrounding the GFR change
equation by validating externally against published stu-
dies. While there are a number of covariate inputs that
are not included in the model, the parameters chosen
are based upon the recommendation of an expert panel
and have all been shown to substantially impact at least
one of the measured outcomes. As new data becomes
available new parameters can be added, however
increasing complexity increases the likelihood of error
and does not necessarily improve accuracy. The goal of
the model is to be as simple as possible while still
reflecting important trends at the population level. The
current covariates are all modifiable and during our sen-
sitivity analyses performed as expected even at their
extremes.
Another limitation is the level of physiologic detail. At
what point are there enough health states to predict
outcomes accurately, but not increase complexity unne-
cessarily? We limit the health states to CKD stage,
ESRD on dialysis (with and without a fistula), ESRD
with a kidney transplant, the presence of cardiac disease
(with and without CHF), the presence of stroke (with
and without moderate to severe disability), and bone
disease. These states all have a significant impact on the
primary outcomes of quality of life and death. As with
covariates, new health states can be added as new data
become available.
Our model is not designed to replace clinical trials or
other primary data gathering. Its purpose is to help inte-
grate a variety of good quality information into a form
that promotes a better understanding of the implications
of potential interventions, and thus more informed deci-
sion making. As demonstrated here, such a model can
help identify variables that are both important and
uncertain, and as such deserve the attention of clinical
researchers.
Conclusion
We developed a model designed to characterize the pro-
gression of CKD and the potential impact of a range of
potentially important interventions. As a public resource
we hope this will serve as a tool for decision makers
and researchers, and will undergo ongoing improvement
in the public domain so that the model will remain cur-
rent and useful.
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